Holen Sie sich die Stockscreener-App
5.4282
16.72%
-1.0918
Schlusskurs vom Vortag:
$6.52
Offen:
$6.52
24-Stunden-Volumen:
112.66K
Relative Volume:
2.40
Marktkapitalisierung:
$9.00M
Einnahmen:
$2.00M
Nettoeinkommen (Verlust:
$-59.61M
KGV:
-5.3469
EPS:
-1.0152
Netto-Cashflow:
$-48.20M
1W Leistung:
-29.48%
1M Leistung:
-35.28%
6M Leistung:
-86.76%
1J Leistung:
-61.24%
1-Tages-Spanne:
$5.42
$6.52
1-Wochen-Bereich:
$5.42
$8.20
52-Wochen-Spanne:
$5.42
$71.50
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
5.4299 | 216.06K | 2.00M | -59.61M | -48.20M | -1.0152 |
VRTX
Vertex Pharmaceuticals Inc
|
433.63 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.48 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.68 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.95 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.56 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-08-13 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
BioAtla Announces 1-for-50 Reverse Stock Split Merger - TipRanks
[8-K] BioAtla, Inc. Reports Material Event - Stock Titan
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm
BioAtla To Carry Out 1-for-50 Reverse Stock Split On April 6th, 2026 - Moomoo
BioAtla Begins Strategic Review Following 2025 Results - TipRanks
BioAtla Announces 50-for-1 Share Consolidation - National Today
BioAtla Announces Share Consolidation - Investing News Network
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
BioAtla announces 50-for-1 reverse stock split effective April 6 - Investing.com
BioAtla to implement 50-for-1 share consolidation - MSN
BioAtla Q4 net loss narrows on lower expenses - TradingView
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - marketscreener.com
BioAtla shrinks share count 50-for-1 to meet Nasdaq's $1 bid rule - Stock Titan
BRIEF-BioAtla Q4 Net Income USD -9.784 Million - TradingView
Strategic shake-up at BioAtla (NASDAQ: BCAB) as oncology pipeline and funding plans are reassessed - Stock Titan
BioAtla (NASDAQ: BCAB) posts 2025 loss, launches asset monetization review - Stock Titan
With $7.1M cash, BioAtla weighs asset sales and slower trial pacing - Stock Titan
Aug Decliners: How much upside does BioAtla Inc haveCPI Data & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Wrap: Will BioAtla Inc stock hit new highs in YEAR2026 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Signal Recap: How much upside does BioAtla Inc have2026 Sector Review & Stepwise Swing Trade Plans - baoquankhu1.vn
Buyout Rumor: Can BioAtla Inc deliver consistent dividends2026 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
BioAtla Shareholders Approve Merger and Share Consolidation - theglobeandmail.com
BioAtla, Inc. 8-K SEC Filing March 17, 2026: Company Information, Key Details, and Legal Disclosures - Minichart
BioAtla (NASDAQ: BCAB) approves merger, 1-for-50 reverse split and 2026 executive retention bonuses - Stock Titan
842,440 shares issued to YA II PN, Ltd.; BioAtla (NASDAQ: BCAB) registers resale - Stock Titan
Breakout Watch: What is the dividend yield of BioAtla IncEarnings Growth Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (NASDAQ: BCAB) to issue 631,163 shares to Yorkville under SEPA - Stock Titan
BioAtla (NASDAQ: BCAB) CMO receives 240,000-share time-based RSU award - Stock Titan
BioAtla (NASDAQ: BCAB) CEO receives 430,000-share RSU grant - Stock Titan
BioAtla (BCAB) CFO awarded 240,000 restricted stock units, total holdings 530,196 shares - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Published on: 2026-03-07 14:29:43 - Naître et grandir
BioAtla launches major restructuring and leadership transition - The Globe and Mail
BioAtla explores sale as it cuts 70% of workforce - Investing.com South Africa
BioAtla (BCAB) CFO sees 1,802 shares withheld for RSU tax settlement - Stock Titan
[Form 4] BioAtla, Inc. Insider Trading Activity - Stock Titan
BioAtla (BCAB) CMO reports 3,140-share tax withholding on RSU vesting - Stock Titan
BioAtla explores sale as it cuts 70% of workforce By Investing.com - Investing.com India
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value - Quiver Quantitative
BioAtla Inc announces 70% workforce reductionSEC filing - marketscreener.com
BioAtla appoints Chris Vasquez as CFO as Richard Waldron departs - TradingView
BioAtla (NASDAQ: BCAB) slashes workforce 70% amid strategic review, listing risk - Stock Titan
BioAtla, Inc. Implements Workforce Reduction of Approximately 70% - marketscreener.com
Bioatla announces formal process to evaluate strategic options to monetize assets - marketscreener.com
Bioatla Announces Formal Process To Evaluate Strategic Options To Monetize Assets - TradingView
Biotech BioAtla to shed 70% of staff while weighing asset sales - Stock Titan
BCAB PE Ratio & Valuation, Is BCAB Overvalued - Intellectia AI
US Market Wrap: Does BioAtla Inc meet Warren Buffetts criteria2025 Retail Activity & Low Drawdown Momentum Ideas - baoquankhu1.vn
Aug Sentiment: Is BioAtla Inc forming bullish engulfing patterns2025 Geopolitical Influence & Long-Term Safe Return Strategies - baoquankhu1.vn
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):